Table 3.
Univariable | Stepwise multivariable | |||
---|---|---|---|---|
Odds ratio (95% CI) | p | Adjusted-OR (95% CI) | p | |
Male sex | 4.22 (1.34–13.28) | .014 | – | – |
Age | 1.03 (0.99–1.07) | .075 | – | – |
Baseline SOFA score | 1.26 (1.09–1.44) | .001 | – | – |
SAPS II score at ICU admission | 1.03 (1.00–1.06) | .043 | – | – |
Baseline creatinine | 1.01 (1.00–1.02) | .038 | – | – |
Vancomycin treatment | 6.42 (2.15–19.12) | .001 | 4.42 (1.39–15.34) | .014 |
All variables related to AKI (within 7 days after drug initiation) in univariate analysis, defined by p < 0.15 are reported, excepted those resumed in the propensity score. Variables with p ≥ 0.15 were not included into the model. All variables entered into the backward stepwise multivariate model including the propensity score were not independently associated with AKI excepted the treatment with vancomycin. AKI acute kidney injury, SOFA Sepsis-Related Organ Failure Assessment, SAPS Simplified Acute Physiology Score